Active Pharmaceutical Ingredients

An Active Pharmaceutical Ingredient (API) is the core chemical constituent of a medicine responsible for its pharmacological action — paracetamol in a fever tablet, metformin in a diabetes drug, or remdesivir in an antiviral formulation. In regulatory terminology, a finished drug consists of one or more APIs combined with excipients (binders, fillers, coatings) that carry, stabilise or deliver the active molecule but exert no therapeutic effect themselves. APIs are also called bulk drugs in Indian usage. Their manufacture is governed in India by the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, enforced through the Central Drugs Standard Control Organisation (CDSCO) under the Drug Controller General of India (DCGI), with Schedule M prescribing Good Manufacturing Practices (GMP). Export-quality APIs must additionally meet pharmacopoeial standards such as the Indian Pharmacopoeia (IP), United States Pharmacopeia (USP) or European Pharmacopoeia.

API synthesis is a multi-stage chemical or fermentation process that begins with Key Starting Materials (KSMs) and intermediates, often built from basic petrochemical or fermentation feedstocks. India is the world's largest supplier of generic medicines by volume — the "pharmacy of the world" — yet it imports roughly 65–70% of its bulk-drug requirement, with the bulk of KSMs and many fermentation-based APIs (antibiotics, vitamins) sourced from China. This dependency, exposed acutely during the COVID-19 supply disruptions of 2020, is the central policy concern. The vulnerability lies less in finished formulation capacity than in the upstream chemistry of intermediates and the cost-competitiveness of Chinese fermentation infrastructure built on cheaper power, scale and historical subsidies.

To reduce this dependence, the Government of India launched the Production Linked Incentive (PLI) Scheme for Bulk Drugs in 2020 (with an outlay of around ₹6,940 crore) covering 41 critical KSMs, drug intermediates and APIs, alongside a Bulk Drug Parks scheme to create shared common infrastructure in states such as Gujarat, Himachal Pradesh and Andhra Pradesh. The aim is self-reliance under the Atmanirbhar Bharat programme in molecules like penicillin G, 7-ACA and key antibiotics. As of 2026, several PLI-backed fermentation units (notably for penicillin G) have commenced commercial production, marking the first domestic manufacture of some intermediates in decades, though import substitution remains partial. Globally, API regulation is reinforced by the US FDA's overseas inspections and the EU's GMP certification, making compliance a competitiveness issue.

For the UPSC examination, APIs feature in the General Studies Paper III segment on science and technology, the economy (drug pricing, exports, manufacturing) and internal/external security of supply chains. The typical question angle probes the strategic risk of import dependence on China, the rationale and instruments of the PLI and Bulk Drug Parks schemes, and India's positioning as a generics exporter. Candidates should connect APIs to the Atmanirbhar Bharat self-reliance narrative, to the price-control mechanism under the Drugs (Prices Control) Order administered by the NPPA, and to public-health access debates. Prelims questions may test the distinction between API and excipient, the regulatory authority (CDSCO/DCGI), and the meaning of "bulk drugs."